Group 1 - Tenglong Co., Ltd. has small batch products indirectly applied in data center/server liquid cooling and energy storage liquid cooling fields [1] - Fuyao Glass reported a 37.33% year-on-year increase in net profit for the first half of 2025, reaching 4.805 billion yuan [2] - Huihong Group plans to dispose of certain financial assets, including stocks of Hongye Futures, Zhongtai Securities, and Shengyi Technology, to optimize asset structure [3] Group 2 - Zhongheng Electric clarified that it has not signed cooperation agreements with overseas cloud companies like NVIDIA, Meta, and Google [4] - Kosen Technology announced it does not produce robot products, despite recent stock price fluctuations [5] - Garden Shares stated it does not have a controlling relationship with Yunzhin Technology [6] Group 3 - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qinggan Granules" has been accepted by the National Medical Products Administration [7] - Zhuochuang Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - Lianhuan Pharmaceutical's new oral solution production line has passed GMP compliance inspection [9] Group 4 - Xianda Co., Ltd. reported a 2561.58% year-on-year increase in net profit for the first half of 2025, reaching 136 million yuan [10] - Jiangte Motor announced that its subsidiary Yichun Silver Lithium will resume production soon [11] - Dameng Data's board member and general manager is under investigation [12] Group 5 - Dongjie Intelligent is planning a change in control, leading to a suspension of its stock and convertible bonds [13] - Gibit reported a 24.50% year-on-year increase in net profit for the first half of 2025, amounting to 645 million yuan [14] - Wuzhou Special Paper's net profit decreased by 47.57% year-on-year to 122 million yuan [15] Group 6 - Harbin Air Conditioning reported a loss of 7.64 million yuan for the first half of 2025, reversing from profit [16] - Tibet Tourism achieved a net profit of 2.09 million yuan, turning around from a loss of 2.58 million yuan in the previous year [17]

Core Insights - Lianhuan Pharmaceutical (600513.SH) announced that its wholly-owned subsidiary, Lianhuan (Anqing), has received the "Drug GMP Compliance Inspection Notification" from the Anhui Provincial Drug Administration [2] - This inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval Number H20243410) and marks the first successful GMP compliance inspection for the newly established oral solution production line [2] - The investment in the oral solution production line amounts to approximately 7.5 million yuan [2]

Group 1 - The company announced that its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., received a notice of compliance inspection for drug GMP from the Anhui Provincial Drug Administration [1] - The inspection will focus on the oral solution dosage form, specifically the production line for oral solution No. 1, scheduled from June 4 to June 7, 2025 [1] - The inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval No. H20243410) [1] Group 2 - As of the announcement date, the investment in the oral solution production line amounts to approximately RMB 7.5 million [1]